 |
54 Diseases |  |
8 Trials |
|
8 Trials |  |
2662 News |  |
| «12...4567891011121314...2324» |
- || ledipasvir/sofosbuvir / Generic mfg.
Biomarker, Clinical, Journal: Cytokine Balance is Restored as Patient Reported Outcomes (PROs) Improve in Patients Recovering from Chronic Hepatitis C (CHC). (Pubmed Central) - Oct 11, 2020
These data indicate relationships between PROs and serum biomarkers pre and post- SVR in CHC. These concomitant changes may have important clinical relevance.
- pibrentasvir (ABT-530) / AbbVie, glecaprevir (ABT-493) / AbbVie
[VIRTUAL] EFFICACY AND SAFETY OF HCV SEROPOSITIVE DONORS TO HCV SERONEGATIVE RECIPIENTS: A LARGE SINGLE CENTER ANALYSIS () - Oct 11, 2020 - Abstract #AASLD2020AASLD_1337;
HCV seropositive donor organs can be safely transplanted into seronegative patients with minimal complications up to 1 year post-transplant. This data supports the continued use of HCV‐seropositive grafts.
- pibrentasvir (ABT-530) / AbbVie, glecaprevir (ABT-493) / AbbVie
[VIRTUAL] VARIABLE ADHERENCE TO HCV TREATMENT AMONG PEOPLE WHO INJECT DRUGS TREATED WITH 8 VERSUS 12 WEEKS OF ANTIVIRAL THERAPY RESULTED IN HIGH RATES OF SVR () - Oct 11, 2020 - Abstract #AASLD2020AASLD_945;
PWID have high rates of SVR and adherence to HCV treatment. Adherence rates were similar for whether they are prescribed an 8- or 12-week course of therapy.
- Sunvepra (asunaprevir) / BMS, Daklinza (daclatasvir) / BMS
[VIRTUAL] SIGNIFICANCE OF IP-10 MEASUREMENT IN PREDICTING POST-DAA TREATMENT LIVER FUNCTION IN PATIENTS WITH HCV-DECOMPENSATED LIVER CIRRHOSIS () - Oct 11, 2020 - Abstract #AASLD2020AASLD_937;
Serum IP-10 levels were decreased in CH/cLC cases upon DAA therapy while such a clear relationship was not observed in dLC cases. Importantly, it was demonstrated that Child-Pugh score was not improved in the dLC cases without IP-10 decrease, indicating that IP-10 dynamics may be useful in predicting liver function after DAA therapy in dLC cases.
- pibrentasvir (ABT-530) / AbbVie, glecaprevir (ABT-493) / AbbVie
[VIRTUAL] SHORT-DURATION OF DIRECT-ACTING ANTIVIRALS IN CANCER PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION () - Oct 11, 2020 - Abstract #AASLD2020AASLD_936;
Background: Short treatment duration of direct-acting antivirals (DAAs) with an 8-week course of ledipasvir/sofosbuvir (LDV/SOF) or glecaprevir/pibrentasvir (GLE/PIB) is approved to treat chronic hepatitis C virus (HCV) infection, but data are sparse on this treatment modality in immunocompromised cancer patients. The use of short-duration of DAAs is very effective and safe in HCV-infected patients with different types of cancer.
- Copegus (ribavirin) / Bausch Health, Vosevi (sofosbuvir/velpatasvir/voxilaprevir) / Gilead
[VIRTUAL] RETREATMENT FOR HCV: PRELIMINARY RESULTS FROM A RETROSPECTIVE ANALYSIS OF POOLED NATIONAL PROGRAM DATA ACROSS LOW- AND MIDDLE-INCOME COUNTRIES () - Oct 11, 2020 - Abstract #AASLD2020AASLD_930;
Additional retrospective data may be collected to study strengths and limitations of these SLT options. These preliminary data can reassure the public, clinicians, and policymakers that effective and affordable SLT options are feasible for national programs in diverse LMICs settings.
- paritaprevir/ritonavir (ABT-450/r) / AbbVie
[VIRTUAL] OUTCOMES OF HEPATITIS C TREATMENT ARE SIMILAR IN CANADIAN INDIGENOUS PEOPLE COMPARED TO NON-INDIGENOUS PATIENTS () - Oct 11, 2020 - Abstract #AASLD2020AASLD_926;
Importantly, DAA SVR rates were comparable to the non-indigenous control group. These real-world effectiveness data add to the limited global data on DAA effectiveness in Indigenous people, and suggests DAA-based HCV microelimination in Indigenous people is possible.
- Sovaldi (sofosbuvir) / Gilead
[VIRTUAL] LONG TERM FOLLOW-UP OF SAFETY AND EFFICACY OF SOFOSBUVIR-BASED HCV DAAS IN PEDIATRIC PATIENTS () - Oct 11, 2020 - Abstract #AASLD2020AASLD_924;
P=N/A
Interim data are reported from a 5-year registry study (NCT02510300) in pediatric patients who received treatment for chronic hepatitis C virus (HCV) infection with sofosbuvir (SOF) +ribavirin (RBV), ledipasvir/sofosbuvir (LDV/SOF) ±RBV, or sofosbuvir/velpatasvir (SOF/VEL) in a prior clinical trial. HCV treatment with the DAAs SOF, LDV/SOF and SOF/VEL resulted in durable SVR in pediatric patients aged 3 to 17 years and did not impact growth or development through a median of 3 years and up to 5 years post-treatment.
- pibrentasvir (ABT-530) / AbbVie, glecaprevir (ABT-493) / AbbVie
[VIRTUAL] EVALUATION OF HOST AND VIRAL FACTORS IN ACHIEVING SUSTAINED VIROLOGIC RESPONSE (SVR) WITH DIRECT-ACTING ANTIVIRALS (DAAS) IN HEPATITIS C VIRUS (HCV) PATIENTS IN THE ILLINOIS DEPARTMENT OF CORRECTIONS (IDOC) () - Oct 11, 2020 - Abstract #AASLD2020AASLD_913;
Despite the presence of factors previously associated with inferior response, study data for this population show no significant difference in the achievement of SVR for incarcerated HCV patients regardless of baseline characteristics. Due to the high achievement of SVR, DAAs should continue to be the standard of care for HCV infections in the correctional population.
- pibrentasvir (ABT-530) / AbbVie, glecaprevir (ABT-493) / AbbVie
[VIRTUAL] DIRECTLY OBSERVED THERAPY FOR HEPATITIS C ALONGSIDE OPIOID AGONIST THERAPY AS AN EFFECTIVE MICRO-ELIMINATION STRATEGY IN VIENNA () - Oct 11, 2020 - Abstract #AASLD2020AASLD_902;
Most common DAA combinations were sofosbuvir/velpatasvir (178, 38%), glecaprevir/pibrentasvir (165, 35.3%) and sofosbuvir/ledipasvir (63, 13.5%). HCV therapy according to the concept of DOT showed excellent SVR12 rates in PWIDs at high risk for non-adherence to DAA therapy.
- pibrentasvir (ABT-530) / AbbVie, glecaprevir (ABT-493) / AbbVie
[VIRTUAL] CRUSHING AND SPLITTING DAAS FOR HCV TREATMENT: A CASE SERIES () - Oct 11, 2020 - Abstract #AASLD2020AASLD_900;
This case series provides evidence for safety and effectiveness with HCV DAA tablet manipulation. More data is needed to further inform practice and treatment decisions.
- pibrentasvir (ABT-530) / AbbVie, glecaprevir (ABT-493) / AbbVie
[VIRTUAL] COMEDICATIONS AND THEIR POTENTIAL DRUG-DRUG INTERACTIONS WITH DIRECT-ACTING ANTIVIRAL AGENTS IN HEPATITIS C PATIENTS ON HEMODIALYSIS () - Oct 11, 2020 - Abstract #AASLD2020AASLD_899;
HCV-viremic patients on hemodialysis had a very high prevalence of comedications with a broad spectrum, which had varied DDIs with currently available DAA regimens. EBR/GZR had the fewest and SOF/VEL/VOX had the most potential DDIs.
- pibrentasvir (ABT-530) / AbbVie, glecaprevir (ABT-493) / AbbVie
[VIRTUAL] ACTIVE DRUG USE IS NOT ASSOCIATED WITH TREATMENT FAILURE AMONG PWID PATIENTS WITH VARIABLE ADHERENCE TO HCV TREATMENT () - Oct 11, 2020 - Abstract #AASLD2020AASLD_895;
Information collected included HCV genotype, treatment regimen, use of opiate substitution therapy (OST; i.e. buprenorphine/naltrexone, methadone), active drug use (patient-reported or positive urine toxicology), adherence and SVR...The most commonly prescribed DAA regimens were: sofosbuvir-velpatasvir (N=11), sofosbuvir-ledipasvir (11 patients; 8 for 12 weeks and 3 for 8 weeks), glecaprevir-pibrentasvir for 8 weeks (N=21), elbasvir-grazoprevir (N=7) and other (N=12)... Among PWID patients who have variable adherence to HCV therapy, active drug use and maintenance on OST during treatment were not associated with treatment failure.
- pibrentasvir (ABT-530) / AbbVie, glecaprevir (ABT-493) / AbbVie
[VIRTUAL] 8 WEEKS VERSUS 12 WEEKS OF DIRECT-ACTING ANTIVIRAL THERAPY FOR KIDNEY TRANSPLANT RECIPIENTS WITH CHRONIC HEPATITIS C INFECTION () - Oct 11, 2020 - Abstract #AASLD2020AASLD_893;
Treatment with 8 weeks of GLE/PIB or LDV/SOF has excellent efficacy in noncirrhotic DDKT patients with HCV. These findings add to the growing evidence of equal efficacy with shorter treatment courses in most HCV patients.
- NATDAC (daclatasvir) / NATCO, Hetero
[VIRTUAL] ON-GOING REGISTRY TO UNDERSTAND PATIENT CHARACTERISTICS AND TREATMENT OUTCOMES IN ADULTS WITH CHRONIC HEPATITIS C INFECTION ACROSS ASIA AND AFRICA () - Oct 11, 2020 - Abstract #AASLD2020AASLD_882;
In this on-going registry of patients with Chronic HCV, sofosbuvir based regimens were effective in the heterogeneous, highly admixed populations across Asia and Africa. Policies should encourage treatment for all Chronic HCV infected patients with sofosbuvir based regimens in Asia and Africa.
- ledipasvir/sofosbuvir / Generic mfg.
[VIRTUAL] LEDIPASVIR/SOFOSBUVIR IN CHRONIC HEPATITIS B PROVIDES MODEST ANTIVIRAL ACTIVITY () - Oct 11, 2020 - Abstract #AASLD2020AASLD_800;
Policies should encourage treatment for all Chronic HCV infected patients with sofosbuvir based regimens in Asia and Africa. Ledipasvir and sofosbuvir are safe and well tolerated when given to CHB subjects, and have a modest antiviral activity particularly when given in combination.
- | Daklinza (daclatasvir) / BMS
Journal, HEOR: Cost-Utility Analysis of Direct-Acting Antivirals for Treatment of Chronic Hepatitis C Genotype 1 and 6 in Vietnam. (Pubmed Central) - Oct 10, 2020
Allocating resources for DAA treatment for HCV genotype 1 and 6 is surely a rewarding public health investment in Vietnam. It is recommended that the government rapidly scale up treatment and enable financial accessibility for HCV patients.
- | Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta
Journal, HEOR: A Cost-Effectiveness Analysis of Glecaprevir/Pibrentasvir Versus Existing Direct-Acting Antivirals to Treat Chronic Hepatitis C in Japan. (Pubmed Central) - Oct 7, 2020
In GT1 treatment-naïve non-cirrhotic patients GLE/PIB was a cost-effective strategy compared to other DAAs. When a pan-genotypic framework was used, the GLE/PIB portfolio dominated the SOF-based portfolio.
- || ledipasvir/sofosbuvir / Generic mfg.
Clinical, P2b data, Journal: Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label study. (Pubmed Central) - Oct 4, 2020
P2b
When a pan-genotypic framework was used, the GLE/PIB portfolio dominated the SOF-based portfolio. In this phase 2b study, ledipasvir combined with sofosbuvir for 12 weeks was safe and effective in patients with genotype 1 HCV infection and stage 4-5 chronic kidney disease who were not on dialysis.
- Sovaldi (sofosbuvir) / Gilead
[VIRTUAL] LONG-TERM Cost-Effectiveness of the Sofosbuvir-Based Directing-Acting Antivirals in Treating Patients with Chronic Hepatitis C (CHC) in China- From a Healthcare Payer’S Perspective () - Oct 3, 2020 - Abstract #ISPOREU2020ISPOR-EU_1910;
SOF-based regimens offer better economic benefits vs PR in China, and provide simpler treatment and broader eligibility vs other DAAs due to being protease inhibitor-free. From a payer’s perspective, SOF-based regimens are more suitable option for CHC treatment in China, with high potential to reduce disease burden and achieve HCV elimination.
- ritonavir / Generic mfg., Daklinza (daclatasvir) / BMS
[VIRTUAL] Real World Evidence in Argentina- Treatment of Patients with Hepatitis C in the Protective System of Emerging Sanitary Technologies (PSEST) () - Oct 3, 2020 - Abstract #ISPOREU2020ISPOR-EU_869;
The real world effectiveness data of patients treated for HCV infection are consistent with those observed in published studies. It should be noted that the number of patients treated does not allow estimating differences in effectiveness between schemes.
- || ledipasvir/sofosbuvir / Generic mfg.
Clinical, Journal: Effectiveness of 8-week sofosbuvir/ledipasvir in the adolescent chronic hepatitis C-infected patients. (Pubmed Central) - Oct 3, 2020
It should be noted that the number of patients treated does not allow estimating differences in effectiveness between schemes. Eight weeks of treatment of SOF/LVD combination is equally effective and safe as 12 weeks in adolescent genotype-4 patients.
- || ledipasvir/sofosbuvir / Generic mfg.
Clinical, Journal: Ledipasvir-Sofosbuvir for 12 Weeks in Children 3 to <6 Years Old With Chronic Hepatitis C. (Pubmed Central) - Oct 3, 2020
Intensive pharmacokinetic analysis of 13 patients for whom data were evaluable confirmed that the doses selected were appropriate. Ledipasvir-sofosbuvir was well tolerated and highly effective in children 3 to <6 years old with chronic HCV infection.
- || ledipasvir/sofosbuvir / Generic mfg.
@GileadSciences failed to cure Hep-C with Remdesevir, but they succeded with Harvoni. Took years. (Twitter) - Oct 3, 2020
- | Daklinza (daclatasvir) / BMS, Sovaldi (sofosbuvir) / Gilead
Journal: Sofosbuvir inhibits yellow fever virus in vitro and in patients with acute liver failure. (Pubmed Central) - Sep 30, 2020
Sofosbuvir may be used as an option for treatment against YFV until other drugs are identified and approved for human use. These results offer insights into the role of nonstructural protein 5 (NS5) in YFV inhibition and suggest that nonstructural proteins may be explored as drug targets for YFV treatment.
- || ledipasvir/sofosbuvir / Generic mfg.
Clinical, Journal: 8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study). (Pubmed Central) - Sep 24, 2020
These results offer insights into the role of nonstructural protein 5 (NS5) in YFV inhibition and suggest that nonstructural proteins may be explored as drug targets for YFV treatment. No abstract available
- || Sovaldi (sofosbuvir) / Gilead, ledipasvir/sofosbuvir / Generic mfg.
Clinical, Journal: Wirelessly Observed Therapy to Optimize Adherence and Target Interventions for Oral Hepatitis C Treatment: Observational Pilot Study. (Pubmed Central) - Sep 24, 2020
No abstract available The findings of this study suggest that digital medicines can be used for wirelessly observed therapy to support adherence to antiviral HCV therapy, reduce unnecessary medication wastage and retreatment costs, and potentially optimize sustained virologic response rates, especially in populations at high risk for nonadherence.
- || Daklinza (daclatasvir) / BMS
Clinical, Journal: Tolerability and effectiveness of generic direct-acting antiviral drugs in eradication of hepatitis C genotype 4 among Egyptian patients. (Pubmed Central) - Sep 23, 2020
The findings of this study suggest that digital medicines can be used for wirelessly observed therapy to support adherence to antiviral HCV therapy, reduce unnecessary medication wastage and retreatment costs, and potentially optimize sustained virologic response rates, especially in populations at high risk for nonadherence. Generic direct antiviral drugs used in treating Egyptian patients with HCV GT-4 demonstrated equal potency, safety and tolerability compared to original brands, with low cost which would help to provide treatment to a larger scale of patients.
- || ledipasvir/sofosbuvir / Generic mfg.
Clinical, P1 data, PK/PD data, Journal: Ledipasvir plus sofosbuvir in pregnant women with hepatitis C virus infection: a phase 1 pharmacokinetic study. (Pubmed Central) - Sep 20, 2020
P1
Ledipasvir-sofosbuvir was safe and effective without clinically meaningful differences in drug exposure among pregnant versus non-pregnant women. National Institutes of Health/Eunice Kennedy Shriver National Institute of Child Health and Human Development, the National Institutes of Health/Office of Research on Women's Health, and Gilead Sciences.
- || ledipasvir/sofosbuvir / Generic mfg.
Clinical, Journal, Real-World Evidence: Real-world effectiveness and safety of Ledipasvir/sofosbuvir for genotype 6 chronic hepatitis C patients in Taiwan. (Pubmed Central) - Sep 16, 2020
National Institutes of Health/Eunice Kennedy Shriver National Institute of Child Health and Human Development, the National Institutes of Health/Office of Research on Women's Health, and Gilead Sciences. The high SVR and excellent safety of LDV/SOF treatment for GT6 CHC patients suggest that LDV/SOF is a favorable option for treating GT6 CHC patients in Taiwan and Asia.
- || Daklinza (daclatasvir) / BMS
Clinical, Journal: Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster-randomised trial. (Pubmed Central) - Sep 16, 2020
P=N/A
Using pharmacists to deliver an HCV care pathway made testing and treatment more accessible for patients, improved engagement, and maintained high treatment success rates. The use of this pathway could be a key part of an integrated and effective approach to HCV elimination at a community level.
- ledipasvir/sofosbuvir / Generic mfg.
[VIRTUAL] New Diagnosis of Autoimmune Hepatitis in a Patient With Remote History of SVR From DAA-Based Hepatitis C Treatment () - Sep 15, 2020 - Abstract #ACG2020ACG_2976;
He was diagnosed with HCV cirrhosis, treated with 12 weeks of sofosbuvir/ledipasvir and achieved sustained virologic response (SVR)...Our patient had successfully completed treatment for HCV with DAA therapy five years before onset of AIH. We present this case not only to highlight an atypical timeline for development of HCV-induced AIH but to emphasize that providers need to maintain a high index of suspicion for AIH in patients with prior history of HCV treated with DAAs who experience subsequent liver injury.
- tacrolimus / Generic mfg.
[VIRTUAL] Management of De novo Malignancy Following Liver Transplantation () - Sep 15, 2020 - Abstract #ACG2020ACG_2743;
The development of secondary malignancies in LT patients is a rare complication with varying presentations. Treatment of malignancies must carefully balance the benefits of decreasing immunosuppressive therapy with the risk of inducing infection or organ rejection.
- pibrentasvir (ABT-530) / AbbVie, glecaprevir (ABT-493) / AbbVie
[VIRTUAL] Factors Predicting Failure of Hepatitis C Therapy in a Diverse Urban Population () - Sep 15, 2020 - Abstract #ACG2020ACG_2576;
The antiviral treatments groups studied were ledipasvir/sofosbuvir (79%), sofosbuvir/velpatasvir (8.3%), elbasvir/grazoprevir (7%), glecaprevir/pibrentasvir (4%), sofosbuvir/velpatasvir/voxilaprevir (1.5%), and other therapies including ombitasvir/paritaprevir/ritonavir and ombitasvir/paritaprevir/ritonavir/dasabuvir (0.4%). These therapies were either given alone or in combination with ribavirin (RBV).
- || ledipasvir/sofosbuvir / Generic mfg.
Clinical, Journal: Safety and Efficacy of 8 Weeks Ledipasvir/Sofosbuvir for Chronic Hepatitis C Genotype 4 in Children Aged 4-10 Years. (Pubmed Central) - Sep 13, 2020
These therapies were either given alone or in combination with ribavirin (RBV). A shortened 8-week regimen of LED/SOF (45/200 mg) is safe and effective with 100% SVR12 in treatment-naïve children with cirrhosis aged 4-10 years with chronic HCV infection genotype 4.
- | Victrelis (boceprevir) / Roche, Merck (MSD), ledipasvir/sofosbuvir / Generic mfg.
Journal: Retreatment of Hepatitis C Infection With Direct-Acting Antivirals. (Pubmed Central) - Sep 12, 2020
All 10 were retreated, and all achieved SVR with ledipasvir/sofosbuvir...Veterans retreated with DAAs for HCV infection had a high success rate. Repeat failures of DAAs were rare, but cirrhosis seems to be common among these patients.
- || ledipasvir/sofosbuvir / Generic mfg.
Clinical, Journal: Retreatment of chronic hepatitis C patients who failed previous therapy with directly acting antivirals: A multicenter study. (Pubmed Central) - Sep 9, 2020
Repeat failures of DAAs were rare, but cirrhosis seems to be common among these patients. The current multicenter study proved the efficacy of various DAAs regimens issued by the National Committee for Control of Viral Hepatitis for retreatment of relapsed CHC Egyptian patients.
- || pibrentasvir (ABT-530) / AbbVie, glecaprevir (ABT-493) / AbbVie, Daklinza (daclatasvir) / BMS
PK/PD data, Review, Journal: Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations: A 2019 Update. (Pubmed Central) - Sep 5, 2020
We briefly discuss the relationship between the pharmacokinetics of the DAAs and efficacy or toxicity in special populations, such as hard to cure patients and patients with liver cirrhosis, liver transplantation, renal impairment, hepatitis B virus or HIV co-infection, bleeding disorders, and children. The aim of this overview is to educate/update prescribers and pharmacists so that they are able to safely and effectively treat HCV-infected patients even in the presence of underlying co-infections or co-morbidities.
- | ledipasvir/sofosbuvir / Generic mfg.
New P3 trial: Efficacy of Sofosbuvir Plus Ledipasvir in Egyptian Patients With COVID-19 Compared to Standard Treatment (clinicaltrials.gov) - Aug 27, 2020
P3, N=250, Completed, Sponsor: Almaza Military Fever Hospital
- | ledipasvir/sofosbuvir / Generic mfg.
Harvoni is one hell of a drug...@GileadSciences 😂 (Twitter) - Aug 25, 2020
- || Daklinza (daclatasvir) / BMS, Sovaldi (sofosbuvir) / Gilead
Clinical, Journal, Real-World Evidence: Effectiveness of sofosbuvir based direct-acting antiviral regimens for chronic hepatitis C virus genotype 6 patients: Real-world experience in Vietnam. (Pubmed Central) - Aug 22, 2020
Our study suggests that patients with HCV genotype 6 infection in Vietnam may respond less well to treatment with sofosbuvir based DAAs than patients with genotype 1 infections. Further studies are needed to confirm this observation and to define whether it is driven by genotype-specific mutations.
- | Journal: Features of resistance-associated substitutions after failure of multiple direct-acting antiviral regimens for hepatitis C. (Pubmed Central) - Aug 22, 2020
R30H and L31-RAS in NS5A were frequently detected after failure of regimens including daclatasvir...S282T RAS in NS5B was detected in 3.9% of ledipasvir/sofosbuvir failures...We investigated RASs after failure of various treatments for chronic hepatitis C, and found that more complicated RASs accumulated in the viral genome with successive failed treatments. The highly resistant P32del RAS at NS5A region was uniquely found in patients for whom DAA treatments had failed, and was linked to the presence and absence of specific RASs.
- || ledipasvir/sofosbuvir / Generic mfg.
Clinical, Journal: Artificial Intelligence Platform Demonstrates High Adherence in Patients Receiving Fixed-Dose Ledipasvir and Sofosbuvir: A Pilot Study. (Pubmed Central) - Aug 22, 2020
Mean (SD) cumulative adherence (visual confirmation of administration) was 91.3% (10.5%). Most subjects (88.2%) achieved ≥80% adherence to treatment, and 88.2% (15 of 17) achieved a sustained virologic response.
- | ledipasvir/sofosbuvir / Generic mfg.
Journal: Generic Ledipasvir-Sofosbuvir Treatment for Adolescents With Chronic Hepatitis C Virus Infection. (Pubmed Central) - Aug 19, 2020
The generic form resulted in a high response rate, significant improvement in liver function, and mild adverse effects. These results are comparable with those of the brand form at a reduced price.
- || ledipasvir/sofosbuvir / Generic mfg.
Yes I have designed antivirals while at Duke and know scientists at CDC worked on Harvoni and Ebola antivirals. (Twitter) - Aug 18, 2020
- || ledipasvir/sofosbuvir / Generic mfg.
Clinical, Journal: Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals. (Pubmed Central) - Aug 14, 2020
P1
This multicenter clinical trial, investigating 8 weeks of ledipasvir/sofosbuvir for acute HCV infections in men with HIV infections, reports a 100% SVR. This study provides the rationale for larger studies of shortened courses of direct-acting antiviral therapies in persons with HIV infections, including those with high baseline HCV RNA loads.
- || tenofovir disoproxil fumarate / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
Clinical, Journal: Increased tenofovir monoester concentrations in patients receiving tenofovir disoproxil fumarate with ledipasvir/sofosbuvir. (Pubmed Central) - Aug 13, 2020
Tenofovir monoester concentrations were increased in individuals receiving TDF with ledipasvir/sofosbuvir, consistent with inhibition of TDF hydrolysis. Additional studies are needed to determine the clinical relevance of this interaction.
- | ledipasvir/sofosbuvir / Generic mfg.
Journal: Low Complement C4 Predicts Improvement of Kidney Function After Direct-Acting Antiviral Therapy for Hepatitis C Virus. (Pubmed Central) - Aug 9, 2020
Patients with low baseline C4 had improved proteinuria, urinary neutrophil gelatinase-associated lipocalin, and interleukin-18 after ledipasvir and sofosbuvir treatment...Twenty patients (40%) had low baseline C4; these patients significantly improved their eGFR (+3.4 ± 11.2 mL/min/1.73 m) compared to those with normal baseline C4 (-4.4 ± 12.2 mL/min/1.73 m; P = 0.028). Low C4 may be a marker of kidney dysfunction that improves with DAA therapy.
- | nitazoxanide / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
New P4 trial: Sofosbuvir/Ledipasvir and Nitazoxanide for Treatment of COVID-19 (clinicaltrials.gov) - Aug 6, 2020
P4, N=240, Recruiting, Sponsor: Assiut University
- || Clinical, Journal: Development of diffuse large B-cell lymphoma after sofosbuvir-ledipasvir treatment for chronic hepatitis C: A case report and literature review. (Pubmed Central) - Aug 6, 2020
Thus, the development of lymphoid malignancies may arise, even after HCV eradication with DAAs. Therefore, clinicians should be aware of such risks during and after antiviral treatment with DAAs.